Altered cytokine levels in pediatric ITP

References

• Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38:1–10
   PubMed Web of Science ®Google Scholar
• Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123–1124
   PubMed Web of Science ®Google Scholar
• Cines DB, Schreiber AD. Immune thrombocytopenia. Use of a Coombs antiglobulin test to detect IgG and C3 on platelets. N Engl J Med 1979;300:106–111
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Kirby MA, Turner C. Role of intravenous immunoglobulin G in autoimmune hematologic disorders. Semin Hematol 1992;29:72–82
   PubMed Web of Science ®Google Scholar
• Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, Freedman J. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: Relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996;87:4245–4254
   PubMed Web of Science ®Google Scholar
• Mouzaki A, Theodoropoulou M, Gianakopoulos I, Vlaha V, Kyrtsonis MC, Maniatis A. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: Their role in prognosis. Blood 2002;100:1774–1779
   PubMed Web of Science ®Google Scholar
• Jernas M, Hou Y, Stromberg Celind F, Shao L, Nookaew I, Wang Q, Ju X, Mellgren K, Wadenvik H, Hou M, et al. Differences in gene expression and cytokine levels between newly diagnosed and chronic pediatric ITP. Blood 2013;122:1789–1792
   PubMed Web of Science ®Google Scholar
• Yajima N, Kasama T, Isozaki T, Odai T, Matsunawa M, Negishi M, Ide H, Kameoka Y, Hirohata S, Adachi M. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: Potential involvement in neuropsychiatric manifestations. Arthritis Rheum 2005;52:1670–1675
   PubMed Web of Science ®Google Scholar
• Ruth JH, Volin MV, Haines GK 3rd, Woodruff DC, Katschke KJ Jr, Woods JM, Park CC, Morel JC, Koch AE. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001;44:1568–1581
   PubMed Web of Science ®Google Scholar
• Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 2007;26:579–591
   PubMed Web of Science ®Google Scholar
• Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693–699
   PubMed Web of Science ®Google Scholar
• Andersson PO, Stockelberg D, Jacobsson S, Wadenvik H. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000;79:507–513
   PubMed Web of Science ®Google Scholar
• Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010;116:4639–4645
   PubMed Web of Science ®Google Scholar
• Wang JD, Chang TK, Lin HK, Huang FL, Wang CJ, Lee HJ. Reduced expression of transforming growth factor-beta1 and correlated elevation of interleukin-17 and interferon-gamma in pediatric patients with chronic primary immune thrombocytopenia (ITP). Pediatr Blood Cancer 2011;57:636–640
   PubMed Web of Science ®Google Scholar
• Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H, Marquardt A, Jagla W, Popp A, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006;290:G827–G838
   PubMed Web of Science ®Google Scholar
• Cheng F, Guo Z, Xu H, Yan D, Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009;68:604–606
   PubMed Web of Science ®Google Scholar
• Lo YH, Torii K, Saito C, Furuhashi T, Maeda A, Morita A. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci 2010;58:225–227
   PubMed Web of Science ®Google Scholar
• Zhang L, Li JM, Liu XG, Ma DX, Hu NW, Li YG, Li W, Hu Y, Yu S, Qu X, et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol 2011;31:606–614
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386–2393
   PubMed Web of Science ®Google Scholar
• Guo C, Chu X, Shi Y, He W, Li L, Wang L, Wang Y, Peng J, Hou M. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 2007;27:557–562
   PubMed Web of Science ®Google Scholar
• Ancuta P, Rao R, Moses A, Mehle A, Shaw SK, Luscinskas FW, Gabuzda D. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003;197:1701–1707
   PubMed Web of Science ®Google Scholar
• Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521–530
   PubMed Web of Science ®Google Scholar
• Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008;112:1078–1084
   PubMed Web of Science ®Google Scholar
• Damas JK, Boullier A, Waehre T, Smith C, Sandberg WJ, Green S, Aukrust P, Quehenberger O. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005;25:2567–2572
   PubMed Web of Science ®Google Scholar
• Matsunawa M, Isozaki T, Odai T, Yajima N, Takeuchi HT, Negishi M, Ide H, Adachi M, Kasama T. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum 2006;54:3408–3416
   PubMed Web of Science ®Google Scholar
• Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271–2279
   PubMed Web of Science ®Google Scholar
• Hu Y, Li H, Zhang L, Shan B, Xu X, Liu X, Xu S, Yu S, Ma D, Peng J, et al. Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. Hum Immunol 2012;73:629–635
   PubMed Web of Science ®Google Scholar